DE60229499D1 - Transfektions-komplexe - Google Patents

Transfektions-komplexe

Info

Publication number
DE60229499D1
DE60229499D1 DE60229499T DE60229499T DE60229499D1 DE 60229499 D1 DE60229499 D1 DE 60229499D1 DE 60229499 T DE60229499 T DE 60229499T DE 60229499 T DE60229499 T DE 60229499T DE 60229499 D1 DE60229499 D1 DE 60229499D1
Authority
DE
Germany
Prior art keywords
seq
peptide
amino acid
transfection complexes
psgx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60229499T
Other languages
English (en)
Inventor
Stephen Lewis Hart
Michele Writer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ICH Productions Ltd
Original Assignee
ICH Productions Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ICH Productions Ltd filed Critical ICH Productions Ltd
Application granted granted Critical
Publication of DE60229499D1 publication Critical patent/DE60229499D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0815—Tripeptides with the first amino acid being basic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Computational Biology (AREA)
DE60229499T 2001-03-14 2002-03-14 Transfektions-komplexe Expired - Lifetime DE60229499D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0106315.5A GB0106315D0 (en) 2001-03-14 2001-03-14 Transfection complexes
PCT/GB2002/001215 WO2002072616A2 (en) 2001-03-14 2002-03-14 Transfection complexes

Publications (1)

Publication Number Publication Date
DE60229499D1 true DE60229499D1 (de) 2008-12-04

Family

ID=9910674

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60229499T Expired - Lifetime DE60229499D1 (de) 2001-03-14 2002-03-14 Transfektions-komplexe

Country Status (9)

Country Link
US (3) US7256043B2 (de)
EP (2) EP1368371B1 (de)
JP (2) JP4430305B2 (de)
AT (2) ATE529434T1 (de)
AU (1) AU2002246226A1 (de)
CA (1) CA2470152A1 (de)
DE (1) DE60229499D1 (de)
GB (1) GB0106315D0 (de)
WO (1) WO2002072616A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0313132D0 (en) * 2003-06-06 2003-07-09 Ich Productions Ltd Peptide ligands
US8062891B2 (en) 2003-10-24 2011-11-22 Gencia Corporation Nonviral vectors for delivering polynucleotides to plants
US20090208478A1 (en) * 2003-10-24 2009-08-20 Gencia Corporation Transducible polypeptides for modifying metabolism
US8133733B2 (en) 2003-10-24 2012-03-13 Gencia Corporation Nonviral vectors for delivering polynucleotides to target tissues
US8507277B2 (en) 2003-10-24 2013-08-13 Gencia Corporation Nonviral vectors for delivering polynucleotides
US20090123468A1 (en) 2003-10-24 2009-05-14 Gencia Corporation Transducible polypeptides for modifying metabolism
ES2411962T3 (es) 2003-10-24 2013-07-09 Gencia Corporation Métodos y composiciones para suministrar polinucleótidos
JP2007043972A (ja) * 2005-08-10 2007-02-22 Tokyo Institute Of Technology アパタイト粒子及びその作製方法、遺伝子−アパタイト粒子複合体及びその作製方法、並びに遺伝子導入方法及び遺伝子導入用キット
EP2437401B1 (de) 2009-05-29 2020-03-11 Sun Patent Trust Drahtlose kommunikationsvorrichtung und frequenzhoppingverfahren dafür
EP2540311A4 (de) 2010-02-26 2016-07-06 Univ Nagasaki Verbundkörper zur verabreichung von antigenen oder heilmitteln
EP3756690A3 (de) * 2013-12-12 2021-03-17 Life Technologies Corporation Membranpenetrierende peptide zur erhöhung der transfektion und zusammensetzungen und verfahren zur verwendung davon
EP3341027B1 (de) 2015-08-28 2024-03-06 Molecular Transfer, Inc. Transfektionskomplexe und verfahren zur verwendung davon
WO2017151733A1 (en) 2016-03-01 2017-09-08 Molecular Transfer, Inc. Plant virus movement proteins and methods of using the same
GB201604235D0 (en) 2016-03-11 2016-04-27 Ucl Business Plc Lipids and complexes for the delivery of biologically-active material to cells
WO2019118806A1 (en) 2017-12-14 2019-06-20 Solid Biosciences Inc. Non-viral production and delivery of genes
GB201800370D0 (en) 2018-01-10 2018-02-21 Ucl Business Plc Anionic nanocomplexes for nucleic acid delivery
GB201803419D0 (en) * 2018-03-02 2018-04-18 Ucl Business Plc Complex for the delivery of cas9 proteins guide RNA to cells
EP4124345A1 (de) 2021-07-30 2023-02-01 4basebio UK Ltd Nanopartikel zur muskelverabreichung
CA3226457A1 (en) 2021-07-30 2023-02-02 Amy WALKER Nanoparticles and peptides for the delivery of cargos to muscle cells
EP4311559A1 (de) 2022-07-29 2024-01-31 4basebio UK Ltd Nanopartikel und peptide zur verabreichung von ladungen in chondrozyten

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6051429A (en) * 1995-06-07 2000-04-18 Life Technologies, Inc. Peptide-enhanced cationic lipid transfections
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
US5923664A (en) * 1996-03-28 1999-07-13 International Business Machines Corporation Method and apparatus providing a multiport physical interface to high speed packet networks
EP0819758B1 (de) * 1996-07-16 2006-09-20 Archibald James Mixson Kationisches Vehikel: DNS Komplexe und ihre Verwendung in Gentherapie
GB9711115D0 (en) * 1997-05-29 1997-07-23 Inst Of Child Health Integrin-targeting vectors having enhanced transfection activity
JP3808632B2 (ja) * 1998-06-18 2006-08-16 富士通株式会社 光増幅器及び光増幅方法
GB9823835D0 (en) * 1998-10-30 1998-12-23 Univ London Component for vaccine
WO2000062815A2 (en) 1999-04-15 2000-10-26 Glaxo Group Limited Novel pharmaceutical composition suitable for gene therapy
US6303573B1 (en) * 1999-06-07 2001-10-16 The Burnham Institute Heart homing peptides and methods of using same
EP1200616A2 (de) 1999-07-29 2002-05-02 Case Western Reserve University Verbesserte verabreichung via serpinenzymkomplex rezeptor liganden
US6885683B1 (en) * 2000-05-23 2005-04-26 Imra America, Inc. Modular, high energy, widely-tunable ultrafast fiber source
US6507430B2 (en) * 2001-02-23 2003-01-14 Photon X, Inc. Long wavelength optical amplifier
KR100424630B1 (ko) * 2002-02-14 2004-03-25 삼성전자주식회사 엘-밴드 어븀첨가 광섬유 증폭기
GB2395353B (en) * 2002-02-18 2004-10-13 Univ Southampton Pulsed light sources
US6990270B2 (en) * 2004-02-11 2006-01-24 Fitel U.S.A. Corp. Fiber amplifier for generating femtosecond pulses in single mode fiber

Also Published As

Publication number Publication date
JP2004532197A (ja) 2004-10-21
WO2002072616A2 (en) 2002-09-19
US20100172930A1 (en) 2010-07-08
GB0106315D0 (en) 2001-05-02
JP4430305B2 (ja) 2010-03-10
ATE529434T1 (de) 2011-11-15
EP1368371B1 (de) 2008-10-22
US20040132973A1 (en) 2004-07-08
US20090060929A1 (en) 2009-03-05
US7256043B2 (en) 2007-08-14
EP1964849A3 (de) 2009-01-21
CA2470152A1 (en) 2002-09-19
ATE412004T1 (de) 2008-11-15
EP1368371A2 (de) 2003-12-10
US8026341B2 (en) 2011-09-27
EP1964849A2 (de) 2008-09-03
EP1964849B1 (de) 2011-10-19
AU2002246226A1 (en) 2002-09-24
WO2002072616A3 (en) 2003-07-03
US7704969B2 (en) 2010-04-27
JP2009131255A (ja) 2009-06-18

Similar Documents

Publication Publication Date Title
ATE412004T1 (de) Transfektions-komplexe
WO2004108938A3 (en) Peptide ligands of dendritic cells for nucleic acid vector targeting
ATE368053T1 (de) Antimikrobielle peptide
DE69535103D1 (de) Rekombinanter adenovirus welcher eine chimäre penton-base aufweist
EP1006126A3 (de) Peptide mit osteogener Aktivität
EP1008351A4 (de) Karzinostatische wirkstoffe
CY1109946T1 (el) Τροποποιημενα πεπτιδια και η χρηση τους για τη θεραπεια αυτοανοσων νοσων
DE69941877D1 (de) Neovaskular-spezifische peptide
DE69935599D1 (de) Modifizierte hcv peptid-impfstoffe
ATE474589T1 (de) Angiogene peptide und ihre verwendungen
WO2001044289A3 (en) Modified leukotoxin gene and protein
EP1557466A4 (de) Tumorantigenprotein und dessen verwendung
DE60036676D1 (de) G-protein-gekoppelter rezeptor-ähnliche proteine
EP1065269A4 (de) Für hm1.24 antigen kodierendes gen und dessen promotor
ATE301199T1 (de) Beta-primeverosidase gen
DE60014655D1 (en) Polypeptide
EP0897984A3 (de) D-Sorbitoldehydrogenase Gen
WO2003018806A1 (fr) Nouveau gene humain bmcc1
EP1295943A4 (de) Polypeptide mit aktivität der stimulierung von neutrophilen
DE69900109D1 (de) Tgf-beta rii rezeptor nukleinsäuresequenz, dadurch kodiertes peptid, und verwendungen davon
HK1050712A1 (en) Wt 1-interacting protein wtip

Legal Events

Date Code Title Description
8364 No opposition during term of opposition